A5101888691- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- Immune cells in cancer
- Allergic Rhinitis and Sensitization
- Urticaria and Related Conditions
- Acne and Rosacea Treatments and Effects
- Sympathectomy and Hyperhidrosis Treatments
- Mycobacterium research and diagnosis
- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Tuberculosis Research and Epidemiology
- Cholinesterase and Neurodegenerative Diseases
- DNA and Nucleic Acid Chemistry
- Pancreatic and Hepatic Oncology Research
- DNA Repair Mechanisms
- Contact Dermatitis and Allergies
- Nail Diseases and Treatments
- Medicine and Dermatology Studies History
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Safety Systems Engineering in Autonomy
- Cancer Genomics and Diagnostics
Washington University in St. Louis
2023-2025
Stanford University
2025
Galderma (United States)
2019-2024
GlaxoSmithKline (United Kingdom)
2022
Saint Louis University
2020
National Institute of Immunology
2011-2012
Research Triangle Park Foundation
2009-2010
GlaxoSmithKline (United States)
2009-2010
GlaxoSmithKline (Canada)
2004-2006
Prurigo nodularis is a chronic pruritic skin disease with multiple nodular lesions. Nemolizumab monoclonal antibody targeting the interleukin-31 receptor, which involved in pathogenesis of prurigo nodularis.
Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis.We sought to evaluate a new dosing strategy of nemolizumab patients with AD.We performed 24-week, randomized, double-blind, multicenter study (10, 30, and 90 mg) subcutaneous injections every 4 weeks versus placebo, topical corticosteroids adults moderate-to-severe AD, severe pruritus, inadequate control treatment (n = 226). The Eczema Area Severity Index (EASI), peak pruritus (PP) numeric rating...
Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. Download PDF Research Summary. In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe to receive initial 60-mg dose nemolizumab followed by subcutaneous injections 30 mg or 60 (depending on baseline weight) every 4...
Pancreatic ductal adenocarcinoma (PDAC) therapeutic resistance is largely attributed to a unique tumor microenvironment embedded with an abundance of cancer-associated fibroblasts (CAF). Distinct CAF populations were recently identified, but the phenotypic drivers and specific impact heterogeneity remain unclear. In this study, we identify subpopulation senescent myofibroblastic CAFs (SenCAF) in mouse human PDAC. These SenCAFs are phenotypically distinct subset that localize near ducts...
Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial acne has not been rigorously studied.Assess safety efficacy trifarotene 50 μg/g cream, a novel topical retinoid, in moderate facial truncal acne.Two phase III double-blind, randomized, vehicle-controlled, 12-week studies once-daily cream versus vehicle subjects aged 9 years or older. The primary end points were rate success on as determined by Investigator's Global Assessment (clear almost clear...
Non–small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths. Immune checkpoint blockade has improved survival for many patients with NSCLC, but most fail to obtain long-term benefit. Understanding the factors reduced immune surveillance in NSCLC critical improving patient outcomes. Here, we show that human harbors large amounts fibrosis correlates T infiltration. In murine models, induction led increased progression, impaired surveillance, and failure efficacy. Associated...
Nemolizumab is a humanized anti-IL-31 receptor blocker in phase 3 for atopic dermatitis (AD).Analyse onset of action nemolizumab 30 mg and compare efficacy safety vs placebo (SC q4wk plus loading dose) moderate-to-severe AD.Post hoc analysis patients with Eczema Area Severity Index (EASI) scores ≥ 16 from 2b trial AD. Endpoints were change EASI score at week 16, peak pruritus numeric rating scale (PP-NRS), Investigator's Global Assessment (IGA), changes sleep responders 4-point improvement...
Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo patients a high burden disease, primarily due to the intensity itch. It is reasonable expect that rapid relief itch - associated improvement are highly valued clinical outcomes for patients. Nemolizumab an IL-31A-receptor inhibitor modulates neuroimmune response reported positive efficacy safety data in phase 2 study PN.To evaluate onset action nemolizumab on...
Background The 9-month-long chemotherapy of tuberculosis often results in poor compliance and emergence drug-resistant strains. So, improved therapeutic strategy is urgently needed. Immunotherapy could be beneficial for the effective management disease. Previously we showed protective efficacy Mycobacterium indicus pranii (MIP) when given as prophylactic vaccine animal models tuberculosis. Methods We sought to investigate whether MIP can used an adjunct guinea pig Efficacy was evaluated...
Background Role of immune system in protecting the host from cancer is well established. Growing however subverts response towards Th2 type and escape antitumor mechanism host. Activation both innate Th1 crucial for activity. In our previous study it was found, that Mycobacterium indicus pranii (MIP) also known as M. w induces activates macrophages animal model tuberculosis. Hence, we studied immunotherapeutic potential MIP mouse tumor underlying mechanisms its Methodology Principal Findings...
Replication protein A (RPA) binds to single-stranded DNA (ssDNA) and interacts with over three dozen enzymes serves as a recruitment hub coordinate most metabolic processes. RPA ssDNA utilizing multiple oligosaccharide/oligonucleotide binding domains based on their individual affinities are classified high versus low-affinity DNA-binding (DBDs). However, recent evidence suggests that the dynamics of DBDs better define roles. Utilizing hydrogen-deuterium exchange mass spectrometry (HDX-MS),...
Targeting tumor-associated macrophages through C-C chemokine receptor type 2 (CCRs) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T cell immunity preclinical models. We conducted a phase I/II single institution study (NCT03496662) combining gemcitabine nab-paclitaxel (GnP), CCR2/5 inhibitor BMS-813160 nivolumab for four 28-day cycles patients with borderline resectable (BR) or locally advanced (LA) PDAC. The recommended dose (RP2D) was...
Abstract Fusion-positive rhabdomyosarcoma (FP-RMS) is an aggressive childhood soft tissue sarcoma, driven by the expression of a fusion oncoprotein PAX3-FOXO1. It presents with high metastatic potential, 80% tumors already at diagnosis, and less than 20% cure rate current available treatment. Paracrine distant signaling, including via small secreted extracellular microvesicles exosomes (sEVs), play critical role in priming pre-metastatic niche enhancing tumor metastasis, but their FP-RMS,...
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that often resistant to therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations in KRAS have both been implicated as drivers of resistance Mitogen-activated protein kinase (MAPK) inhibition has not yet shown clinical efficacy, likely because rapid acquisition tumor-intrinsic resistance. However, the unique PDAC TME may also be driver We found long-term focal adhesion (FAK) inhibitor treatment led...
Abstract Background Atopic dermatitis (AD) is a common, chronic, and flaring itchy inflammatory skin disease requiring long-term treatment. Nemolizumab significantly improved lesions, itch, sleep through Week (W) 16 in two global phase 3 studies (ARCADIA-1 [NCT03985943] ARCADIA-2 [NCT03989349]) adolescents adults with moderate-to-severe AD.1 Introduction/Background To evaluate the efficacy safety of maintenance treatment nemolizumab background topical therapy for up to 32 weeks patients (≥12...
SUMMARYBackground: A new oral form of sumatriptan has been developed to facilitate tablet disintegration and drug dispersion mitigate the effects gastric stasis that can accompany migraine.Objective: To evaluate on functional ability fast disintegrating/rapid release formulation sumatriptan.Methods: Sumatriptan 50 mg (n = 137), 100 142), or placebo 153) was administered early when pain mild for acute treatment a single migraine attack in randomized, double-blind, parallel-group,...
There is evidence that headache response rates may be higher if triptans are used early when a migraine attack still mild, as compared to it treated after pain has reached moderate or severe intensity.In this randomized, double blind, placebo controlled, parallel group clinical trial, 361 patients took either placebo, sumatriptan 50 mg, 100 mg in single study. The primary outcome measure was pain-free status at two hours.In the intention treat group, hour free were 16%, 40%, and 50%...
The test characteristics of rapid tests for respiratory syncytial virus (RSV) in infants may differ from older children secondary to a lower likelihood previous illness with RSV. Our main goal was establish the RSV Abbott Testpack (TP) enzyme-linked immunoabsorbent assay (EIA) ® febrile < 60 days age. determine given particular clinical syndrome and negative or positive EIA. A prospective sample temperature > 38.0 0 C evaluated during 2 successive seasons. Conventional tissue shell...